Johnny C. Taylor Jr., a human-resources expert, is tackling your questions as part of a series for USA TODAY. Taylor is president and CEO of the Society for Human Resource Management, the world’s largest HR professional society.
The questions submitted by readers and Taylor’s answers below have been edited for length and clarity.
Question: My friend is an Air Force veteran who is now a member of the reserves. She has been trying to get an entry-level IT job at a New York financial firm and has had two final interviews but has not been hired. I believe she was turned down because of discrimination against her reservist status. She trained as a medical technician for 10 years but then used the GI Bill to get her bachelor’s degree in IT from a good school. How do you recommend she address HR questions related to her military service? Are there any recruitment firms that help military members with entry-level jobs where their past skills are not a perfect match? – Tony
Top 10 Medical Stocks To Watch For 2019: Oasis Petroleum Inc.(OAS)
Advisors’ Opinion:
- [By Stephan Byrd]
UBS Group AG cut its holdings in Oasis Petroleum Inc. (NYSE:OAS) by 2.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 730,530 shares of the energy producer’s stock after selling 15,269 shares during the quarter. UBS Group AG’s holdings in Oasis Petroleum were worth $5,917,000 as of its most recent SEC filing.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Oasis Petroleum (OAS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Royal Dutch Shell (NYSE:RDS.A) and Oasis Petroleum (NYSE:OAS) are both oils/energy companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.
- [By Stephan Byrd]
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
Get Oasis Petroleum alerts:
Oasis Petroleum CEO: Oil prices always come back to suppl… (finance.yahoo.com) Oasis Petroleum (OAS) Price Target Raised to $17.00 at JPMorgan Chase (americanbankingnews.com) Oasis Petroleum (OAS) Rating Increased to Overweight at Morgan Stanley (americanbankingnews.com) Oasis Petroleum (OAS) Given Buy Rating at Williams Capital (americanbankingnews.com) Oasis Petroleum (OAS) Forecasted to Post FY2018 Earnings of $0.44 Per Share (americanbankingnews.com)
Several equities research analysts have recently commented on the stock. Stephens set a $15.00 price target on shares of Oasis Petroleum and gave the stock a “buy” rating in a research report on Tuesday, April 24th. Williams Capital reiterated a “buy” rating and set a $18.00 price target on shares of Oasis Petroleum in a research report on Wednesday. JPMorgan Chase & Co. set a $17.00 price target on shares of Oasis Petroleum and gave the stock a “buy” rating in a research report on Wednesday. Morgan Stanley upgraded shares of Oasis Petroleum from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $12.52 to $19.00 in a research report on Wednesday. Finally, BMO Capital Markets lifted their price target on shares of Oasis Petroleum from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 1st. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and sixteen have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $12.41.
- [By Matthew DiLallo]
Shares of Oasis Petroleum Inc. (NYSE:OAS) rallied 13.2% in August, primarily due to the oil driller’s stronger-than-expected second-quarter report.
- [By Matthew DiLallo]
Oasis Midstream Partners is also an MLP created by an oil company, though its parent, Oasis Petroleum (NYSE:OAS), isn’t quite as well known as the other two. It’s also new to the market since it just went public last year. However, it does have two things that set it apart.
Top 10 Medical Stocks To Watch For 2019: Alaska Air Group, Inc.(ALK)
Advisors’ Opinion:
- [By ]
Cramer was bearish on Grubhub (GRUB) , Sprint (S) , LG Homes (LGIH) , Acadia Pharmaceuticals (ACAD) , Pilgrim’s Pride (PPC) , Opko Health (OPK) , Alaska Air Group (ALK) and Winnebago Industries (WGO) .
- [By Lee Jackson]
This company has a big west coast exposure and continues to rank high on Wall Street. Alaska Air Group Inc. (NYSE: ALK) is the parent company of Alaska Airlines, and it reported impressive traffic data buoyed by strong demand. The company serves more than 100 cities through an expansive network in Alaska, the Lower 48 states, Hawaii, Canada and Mexico. Despite recent challenges by other carriers for superiority in the Northwest, the company has strong customer loyalty, which has contributed to outstanding earnings and revenue growth.
- [By ]
Alaska Air Group (ALK) : “It used to be the best before the acquisition and now it’s not great and I can’t recommend it anymore.”
Winnebago Industries (WGO) : “This group trades badly. All we hear about is an inventory glut. We need someone to tell us otherwise.”
- [By Adam Levine-Weinberg]
Southwest still needs to get FAA approval before it can begin ticket sales, but on Thursday, it offered more details of its plans for Hawaii. Based on Southwest’s service proposal, Alaska Air (NYSE:ALK) could be forced to significantly scale back its presence in the Hawaii market.
- [By Adam Levine-Weinberg]
Alaska Air’s (NYSE:ALK) dismal earnings trend continued last week, as it posted a sharp drop in profit for the second quarter. So far, the third quarter is shaping up to be just as bad. Alaska Airlines’ guidance implies another big profit decline.
- [By Adam Levine-Weinberg]
The last couple of years have not been kind to JetBlue Airways (NASDAQ:JBLU) and Alaska Air Group (NYSE:ALK). Rising fuel prices have pinched profitability across the U.S. airline industry, but due to competitive dynamics and other factors, JetBlue and Alaska have had more trouble offsetting these cost headwinds than some other carriers.
Top 10 Medical Stocks To Watch For 2019: HSBC Holdings PLC (HSBA)
Advisors’ Opinion:
- [By Ethan Ryder]
HSBC (LON:HSBA) had its price target dropped by equities research analysts at Citigroup from GBX 810 ($10.78) to GBX 800 ($10.65) in a report released on Tuesday. The brokerage currently has a “buy” rating on the financial services provider’s stock. Citigroup’s price target points to a potential upside of 9.59% from the stock’s previous close.
- [By Joseph Griffin]
HSBC (LON:HSBA) had its target price lowered by equities research analysts at Shore Capital from GBX 721 ($9.60) to GBX 625 ($8.32) in a report issued on Tuesday. The brokerage presently has a “sell” rating on the financial services provider’s stock. Shore Capital’s price objective indicates a potential downside of 14.71% from the company’s previous close.
- [By Max Byerly]
Credit Suisse Group set a GBX 720 ($9.32) price target on HSBC (LON:HSBA) in a research report sent to investors on Tuesday morning. The firm currently has a neutral rating on the financial services provider’s stock.
- [By Max Byerly]
HSBC Holdings plc (LON:HSBA) has received an average recommendation of “Hold” from the sixteen analysts that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is GBX 768.33 ($9.80).
Top 10 Medical Stocks To Watch For 2019: PetroChina Company Limited(PTR)
Advisors’ Opinion:
- [By Max Byerly]
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect PetroChina (PTR) Stock Price” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at www.tickerreport.com/banking-finance/3368551/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-petrochina-ptr-stock-price.html.
- [By Ethan Ryder]
PetroChina (NYSE: PTR) and Callitas Health (OTCMKTS:MPHMF) are both oils/energy companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.
- [By Max Byerly]
Gabelli Funds LLC lessened its holdings in shares of PetroChina Company Limited (NYSE:PTR) by 34.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,800 shares of the oil and gas company’s stock after selling 2,000 shares during the quarter. Gabelli Funds LLC’s holdings in PetroChina were worth $290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Top 10 Medical Stocks To Watch For 2019: Sage Therapeutics, Inc.(SAGE)
Advisors’ Opinion:
- [By Joseph Griffin]
Stevens Capital Management LP bought a new stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 3,223 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.
- [By Maxx Chatsko]
After sliding 41.8% in 2018, shares of Sage Therapeutics (NASDAQ:SAGE) jumped nearly 49% last month, according to data from S&P Global Market Intelligence. The sudden leap came after the company reported impressive results for SAGE-217 in a phase 3 trial studying the drug candidate as a potential treatment for postpartum depression.
- [By Dan Caplinger]
Tuesday saw a mixed session on Wall Street, with various market benchmarks moving in different directions. Investors seemed reasonably neutral about events in Singapore, where leaders from the U.S. and North Korea met and came to some minor agreements that viewed in the most favorable light could provide a road map for future negotiations. Yet investors seem more concerned about what the Federal Reserve’s interest rate setting board might do later in the week, with a two-day meeting starting today to consider whether further rate increases are warranted. Even with the relatively flat performance from the market, some companies had good news that sent their shares sharply higher. Tesla (NASDAQ:TSLA), Sage Therapeutics (NASDAQ:SAGE), and Lands’ End (NASDAQ:LE) were among the best performers on the day. Here’s why they did so well.
- [By Shane Hupp]
SG Americas Securities LLC acquired a new position in SAGE Therapeutics Inc (NASDAQ:SAGE) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,233 shares of the biopharmaceutical company’s stock, valued at approximately $843,000.
- [By Chris Lange]
Sage Therapeutics, Inc. (NASDAQ: SAGE) shares made a handy gain on Tuesday after the firm announced its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the U.S. Food and Drug Administration (FDA).
- [By ]
Cramer was bearish on Geron (GERN) , Mitek Systems (MITK) , AK Steel Holding (AKS) , Sage Therapeutics (SAGE) and AbbVie (ABBV) .
Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.
Top 10 Medical Stocks To Watch For 2019: Aethlon Medical, Inc.(AEMD)
Advisors’ Opinion:
- [By Shane Hupp]
Get a free copy of the Zacks research report on Aethlon Medical (AEMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Aethlon Medical (NASDAQ: AEMD) is one of 23 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Aethlon Medical to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
- [By Max Byerly]
Aethlon Medical (NASDAQ: AEMD) is one of 23 public companies in the “Analytical instruments” industry, but how does it contrast to its rivals? We will compare Aethlon Medical to related businesses based on the strength of its profitability, valuation, analyst recommendations, earnings, risk, dividends and institutional ownership.
Top 10 Medical Stocks To Watch For 2019: Approach Resources Inc.(AREX)
Advisors’ Opinion:
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Approach Resources (AREX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Approach Resources (AREX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Approach Resources Inc. (NASDAQ:AREX) hit a new 52-week low during trading on Thursday . The company traded as low as $2.02 and last traded at $2.04, with a volume of 2875 shares trading hands. The stock had previously closed at $2.08.
- [By Max Byerly]
Get a free copy of the Zacks research report on Approach Resources (AREX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Media headlines about Approach Resources (NASDAQ:AREX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Approach Resources earned a coverage optimism score of 0.02 on Accern’s scale. Accern also gave press coverage about the energy company an impact score of 46.8987147373518 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
- [By Joseph Griffin]
Shares of Approach Resources Inc. (NASDAQ:AREX) have received an average recommendation of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $2.75.
Top 10 Medical Stocks To Watch For 2019: Diageo plc(DEO)
Advisors’ Opinion:
- [By Stephan Byrd]
MUFG Americas Holdings Corp lowered its holdings in Diageo plc (NYSE:DEO) by 6.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,465 shares of the company’s stock after selling 595 shares during the quarter. MUFG Americas Holdings Corp’s holdings in Diageo were worth $1,219,000 as of its most recent filing with the SEC.
- [By Jeremy Bowman]
Diageo (NYSE:DEO), the global alcohol giant that owns Guinness beer and Smirnoff vodka, has held discussions with at least three marijuana growers, though it has yet to make a deal, and Heineken’s (NASDAQOTH:HEINY) Lagunitas brand launched a THC-infused beverage back in June, which is currently available in California dispensaries.
- [By Keith Speights]
There’s another Canadian marijuana market that won’t open for business in October in which investors appear to be hoping Tilray will be a major contender. Cannabis edibles (including cannabis-infused beverages) and concentrates won’t be allowed until next year. Large British alcoholic beverage maker Diageo plc (NYSE:DEO) is reportedly looking for a cannabis partner to target this market. Tilray could be one of Diageo’s top candidates.
- [By Logan Wallace]
Media headlines about Diageo (NYSE:DEO) have trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Diageo earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.680770361691 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
- [By Stephen Mack]
Aside from major corporations like The Hershey Co. (NYSE: HSY) and Diageo Plc. (NYSE: DEO), ServiceNow clients include giant institutions such as CERN, the European physics lab that employs 12,000 scientists, and New York City’s 6,000-employee Department of Health.
- [By Keith Speights]
BNN Bloomberg reported late last week that U.K.-based beverage company Diageo plc (NYSE:DEO), the maker of Guinness beer and Smirnoff vodka, has been in talks with at least three Canadian marijuana growers. No firm details are available at this point. However, several stocks of cannabis producers have soared on speculation that they could be the next to snag a deal.
Top 10 Medical Stocks To Watch For 2019: TD Ameritrade Holding Corporation(AMTD)
Advisors’ Opinion:
- [By ]
TD Ameritrade Holding Corp. (AMTD) has made crypto history as the first firm ever to place an advertisement on the blockchain. “Through a series of transactions we became the first brand to place an ad in the blockchain. Why? Well, we love finding new ways to use emerging technology. So we decided to have a little fun and plant our flag,” TD wrote on its website, where it included a photo of the ad embedded right into the blockchain code. The process took 68 transactions and TD used the OP_Return feature in bitcoin’s protocol to insert characters as one might write a memo on a check. The resulting transactions were invalid, but they remain preserved on the blockchain ledger for as long as it exists.
- [By Jon C. Ogg]
TD Ameritrade Holding Corp. (NASDAQ: AMTD) is the second largest discount and online broker by market value, with a $32 billion market cap. Its shares were down almost 6% at $56.65 after the JPMorgan news. TD Ameritrade has a consensus price target of $68.32 and a 52-week range of $42.14 to $63.01.
- [By Logan Wallace]
TD Ameritrade (NASDAQ:AMTD) announced a quarterly dividend on Monday, April 23rd, RTT News reports. Shareholders of record on Tuesday, May 8th will be paid a dividend of 0.21 per share by the financial services provider on Tuesday, May 22nd. This represents a $0.84 annualized dividend and a yield of 1.42%. The ex-dividend date is Monday, May 7th.
Top 10 Medical Stocks To Watch For 2019: Transmontaigne Partners L.P.(TLP)
Advisors’ Opinion:
- [By Joseph Griffin]
Get a free copy of the Zacks research report on TransMontaigne Partners (TLP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Shares of TransMontaigne Partners L.P. (NYSE:TLP) have received a consensus recommendation of “Hold” from the seven research firms that are currently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $40.75.
- [By Shane Hupp]
Get a free copy of the Zacks research report on TransMontaigne Partners (TLP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Shane Hupp]
Get a free copy of the Zacks research report on TransMontaigne Partners (TLP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com